A recent study published in the journal PloS ONE showed that THC and CBD can inhibit the proliferation of cancer cells in lung cancer.
Patients with non-small cell lung cancer (NSCLC) often develop resistance to anti-tumor agents. New complementary drugs are then needed. This study looked at endocannabinoid receptor agonists (CB1 and CB2), in this case, THC and CBD.
According to the researchers, the combined use of THC and CBD confers greater benefits because CBD enhances the effects of THC and reduces its psychotropic activity. They evaluated the relationship between the expression levels of CB1 and CB2 receptors in patients with NSCLC. And the effect of THC and CBD (individually and in combination) on, among other things, cancer proliferation.
Thus, patients with high expression levels of CB1 and/or CB2 receptors showed increased survival.
Both cannabinoid agonists inhibited the proliferation and expression of lung cancer cells, and CBD potentiated the effect of THC.
THC and CBD alone or in combination reduced the in vitro migration of the three lung cancer cell lines used.
The study concludes that CB1 and CB2 receptor expression levels are a potential use as markers of survival in non-small cell lung cancer patients.
THC and CBD also inhibited the proliferation and expression of the lung cancer cells studied. Also, the THC/CBD combination restored the epithelial phenotype in vitro.